Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
Researchers have created a detailed molecular map of the thromboxane A2 receptor, which could lead to the development of safer and more effective therapies targeting this clinically important signalling system. The study reveals an unusual activation switch and provides insights into how signalling molecules interact with the receptor.
Researchers at Umeå University have discovered a key protein that helps cancer cells survive treatment by blocking apoptosis. The study provides a deeper understanding of how proteins interact within the cell, which could lead to new cancer therapies targeting Bcl-2 and its protective function.
Researchers reveal that immune system's T cells travel to the prostate to provide long-term protection against infections. Harnessing these disease-fighting cells could lead to new therapies for prostate cancer and inflammatory conditions.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
A study by Princeton University researchers found that high-fat diets contribute to aggressive breast cancer growth, with tumors fed fatty acids forming hollow appendages. The team's 3D model showed that a ketogenic diet did not provide the expected benefits for this type of cancer.
A new blood-based biomarker has been discovered to help identify individuals at higher risk of developing cancer in people with Lynch Syndrome. The biomarker uses immune signatures detected in blood samples to provide unique characteristics that can detect cancer risk, allowing for early detection and personalized surveillance.
Salk Institute researchers have developed a new biological platform for studying mitochondrial DNA in human physiology, adaptation, and therapeutic development. The platform allows scientists to investigate mitochondrial DNA variation in health and disease, enabling therapeutic innovation for mitochondrial disorders.
A new study found that metformin raises levels of N-lactoyl-phenylalanine, a molecule tied to energy balance and weight control, in men with prostate cancer. This finding suggests metformin could help counter metabolic strain caused by hormone therapy, which often limits physical activity.
Researchers at the University of Mississippi have developed a new method for delivering cancer-fighting drugs using 3D-printed nanocarriers, which can target specific tumor sites and minimize side effects. This innovative approach has shown promising results in killing cancer cells and reducing the impact of traditional chemotherapy.
A new, cost-effective blood test detects liver, lung, ovarian, stomach cancers, and various non-cancer conditions by analyzing DNA fragments in the bloodstream. The test achieved high accuracy rates for multi-cancer detection and tissue-of-origin identification.
The COCOON trial found that a structured dermatologic prophylaxis regimen reduced moderate-to-severe dermatologic adverse events by half, with fewer grade ≥3 events and treatment discontinuations. This approach could improve tolerability and maintain dose intensity for EGFR-mutant non-small cell lung cancer patients.
A Waseda University research team developed a nanotube membrane-based injector to directly and reliably manipulate the cytoplasmic composition of living cells. The system successfully transferred cytoplasmic contents, including mitochondria, into target cells with high efficiency and minimal damage.
Renowned cancer scientist Thales Papagiannakopoulos is joining the Salk Institute as a professor, bringing expertise in cancer metabolism and immunology. He will collaborate with colleagues to uncover how tumors interact with the nervous system and develop new therapeutic strategies.
Fábio Rosa's research has enabled genetic reprogramming of various cancer cell types to activate the immune system and bring about their own destruction. His approach uses tools from gene therapy to generate rare and functionally specialized immune cells that trigger powerful anti-tumor responses.
Researchers reveal that high levels of hypoxia-inducible factor-2 (HIF-2) in pancreatic tumor microenvironment protects cells from ferroptosis, a promising target for therapy. The study identifies key biochemical pathways activated by HIF-2 to limit ferroptotic cell death.
Researchers developed first-in-class dual HIF inhibitors that, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice. The drugs target HIF-1/2 transcription factors, which are key regulators of cancer progression.
Scientists discovered how tumors disable dendritic cell function by decreasing their mitochondrial fitness, leading to weakened immune defenses against cancer. Restoring mitochondrial function in dendritic cells improves antitumor immune responses and enhances immunotherapeutic efficacy.
A study reveals CHKA and EGFR cooperate to activate the MAPK pathway, driving glioma progression. CHKA knockdown suppresses tumor growth, while EGFR overexpression rescues this effect.
Researchers identified DMBT1 as a key target of Lentinus edodes-derived β-glucan in inhibiting cervical cancer progression. The compound's anti-cancer activity was shown to be closely correlated with DMBT1 expression levels, suggesting its potential as a prognostic marker or therapeutic target.
The NCCN Foundation recognizes five young investigators for their promising research on cancer innovation, providing $100,000 grants to advance their work and strengthen the pipeline for cancer success.
Researchers created a CRISPR-based tool to pinpoint genes the cancer turns off, restoring a key cancer-fighting gene in leukemia. The study found that blocking KDM4 enzymes can regain expression of the tumor-suppressor gene ZBTB7A, reducing leukemia burden while leaving normal blood formation largely unaffected.
Researchers at University of Liège develop mouse model to study Stard7's role in intestinal cancers, revealing protein's dual effects on tumour development. In some cases, Stard7 deficiency reduces tumour growth, while in others it accelerates it.
Researchers developed a blood-based test that analyzes circulating tumor HPV DNA to inform personalized treatment strategies for HPV-associated throat cancer. The study found that ctDNA levels change before and after surgery, influenced by tumor biology and kidney function.
According to a new study published in The Lancet, childhood cancer is the eighth-leading cause of death among children worldwide. Researchers found that over 377,000 new cases and 144,000 deaths occurred in 2023, with most cases in low- and middle-income countries.
Researchers found that targeting MD2 could reduce tumor growth in a mouse model of prostate cancer bone metastasis. High MD2 expression was associated with metastasis, immune suppression, and increased resistance to PARP inhibitor therapy.
The NCCN 2026 Annual Conference emphasized the need for holistic care for adolescents and young adults with cancer, highlighting unique challenges and the importance of supportive services. The conference also addressed global cancer care realities and future strategies, emphasizing the need for collaboration and investment to address ...
A phase 1/2 clinical study found that pralsetinib improved durable responses with manageable safety profiles in patients with advanced or metastatic RET fusion-positive non-small cell lung cancer. The overall response rate was 78% and median duration of response was longer in patients with the CCDC6-RET fusion gene.
A study published in Nature Health reveals a strong link between pesticide exposure and the risk of developing certain cancers. The research shows that pesticide exposure increases the risk of cancer by 150% in areas with high levels of pollution, and highlights early biological effects before cancer develops.
Researchers have developed a potential non-invasive treatment for melanoma using a stretchy, heat-activated skin patch that releases copper ions to kill cancer cells. The patch reduced melanoma lesions by 97% in a preliminary animal study, with no damage to surrounding tissue.
Mohamed Abou-el-Enein, a USC physician-scientist, has received the Outstanding New Investigator Award and Best of Molecular Therapy Award from the American Society of Gene + Cell Therapy. His work focuses on translating scientific discoveries into clinical applications, with a particular emphasis on cell therapies.
A team from UNIGE has created a molecular system that distinguishes and neutralises cancer cells with unprecedented precision, paving the way for autonomous, self-regulating drugs. The technology uses synthetic DNA strands to deliver potent drugs only where they are needed, reducing damage to healthy tissue.
A study by UC San Diego researchers reveals TYK2's role in preventing cancer spread and highlights need for enhanced screening in patients treated with TYK2 inhibitors. Understanding mechanotransduction can provide new avenues for treatment and improve breast cancer outcomes.
Researchers found that the three-drug combination increased autophagosome formation and autophagic flux in uveal melanoma cells, killing them via enhanced autophagy. The study suggests a potential therapeutic approach for treating metastatic uveal melanoma, particularly in liver-targeted disease.
The new joint department combines expertise in medical devices, neuroengineering, imaging science, and more to advance biomedical research and translate discoveries into meaningful health advances. The partnership aims to accelerate the translation of discoveries into improvements in human health.
A study led by Brown University researchers analyzed lung screening data to identify abnormalities outside the lungs that warrant follow-up care. Cancer-related findings appeared in about 3% of screening rounds and were linked to a higher risk of extrapulmonary cancers, particularly urinary system cancers.
Researchers used machine learning methods to identify safe time windows for outpatient stem cell therapy in multiple myeloma patients. The study found that this approach can predict adverse events and enable more precise risk assessment.
The San Antonio Breast Cancer Symposium generated nearly $40 million in economic impact and drew over 11,000 attendees from 104 countries. The symposium also produced $1.5 million in local tax revenue and supported more than 6,800 jobs.
A framework has been developed to identify candidate pathogenic variants hidden among uncertain significance variants detected in comprehensive genomic profiling. The framework was tested using BRCA1 and BRCA2 genes, leading to the classification of a previously unknown variant as pathogenic.
Research systematically maps how bacterial metabolites influence disease progression and immune cell functions, highlighting their dual effects on the body. The review emphasizes the need for holistic regulation of metabolite profiles to achieve precision interventions.
Researchers created a detailed map of neuroblastoma, a childhood cancer, using cutting-edge technology. They found that high-risk tumors carry a defense mechanism against ferroptosis, a natural cancer-killing process, but it's shielded by the protein GPX4.
A new genetic 'roadmap' provides a navigational framework for more precise diagnosis and treatment of intrahepatic cholangiocarcinoma. The framework identifies five molecular subtypes, each associated with distinct therapeutic vulnerabilities, enabling targeted treatment strategies.
Among highly boosted patients with cancer, overall postacute sequelae risk was not elevated compared to noninfected patients; hospitalized COVID-19 patients remained at increased risk despite therapeutics. Vaccination and boosting remain important in mitigating long COVID among immunocompromised patients
A new study by UNSW Sydney and published in Carcinogenesis suggests that nicotine-based vapes are likely to cause cancers of the lung and oral cavity. The research, led by Adjunct Professor Bernard Stewart AM, analyzed global research and found consistent findings across multiple disciplines.
A team of researchers has created a 3D model of pediatric brain tumors using biopsy-derived organoids, allowing for more accurate testing of new drugs. The model, which accurately reproduces the human environment, preserves the molecular characteristics of the original tumor and maintains cellular heterogeneity.
Researchers have discovered a tumor biomarker that can predict which gastric cancer patients will benefit from immunotherapy before surgery. The biomarker, tsMHC-II expression, showed strong correlation with treatment response and was easily assessable using standard immunohistochemistry techniques.
The BiliSeq test detected approximately 82% of bile duct cancers, compared to 44% with pathology alone, and increased cancer detection to nearly 90% when combined with pathology. This improved accuracy enables physicians to provide more personalized medicine and treatment options for patients.
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center has been awarded a $3 million National Cancer Institute Career Development Award to support early-career oncology researchers focused on improving cancer outcomes for patients from diverse backgrounds. The program, called Advancing Oncology Research C...
Researchers found that combining targeted radiation therapy with BO-112 and anti-PD-1 therapy before surgery activated the immune system to fight cancer. This approach reshaped the tumor microenvironment to support T-cell activity, resulting in fewer cancer cells and a more effective anti-tumor response.
Researchers at Trinity College Dublin and their colleagues are developing a simple, high-accuracy blood test to detect bowel cancer. The CASPDx CRC test aims to transform cancer outcomes by moving screening away from invasive methods.
A recent study published in JAMA Oncology suggests that obesity control is a potentially effective strategy for cancer prevention. The research reveals that successful weight management can lead to a significant reduction in the risk of various cancers, making it an underutilized approach in cancer prevention.
Researchers discovered a new type of protein modification related to cellular mutation that impairs an enzyme's ability to help drive energy processes. The discovery opens a new route to therapeutic cancer intervention, particularly for IDH mutations common in multiple cancer cells.
A new study published in PLOS Medicine found that consistently meeting physical activity guidelines throughout middle age reduces women's risk of dying from any cause by half. The study, which tracked over 11,000 Australian women, also found strong benefits for cardiovascular disease and cancer mortality.
NYU faculty Eray Aydil, André Fenton, Anirban Maitra, and Liina Pylkkänen recognized for their groundbreaking work in materials synthesis, neuroscience, cancer research, and language processing. The American Association for the Advancement of Science has selected 449 members as AAAS Fellows this year.
Researchers have reported early, reassuring results from the LORD trial on active surveillance for low-risk DCIS. The study found that patients with active surveillance did not experience worse early outcomes compared to those who underwent immediate surgery, and that many chose active surveillance over surgery.
A new platform called ATLAS enables researchers to generate large quantities of cancer cell clusters that accurately model metastasis. Using ATLAS, the Rice team gained insights into the mechanisms that enable cancer clusters to survive in the bloodstream during the metastatic process.
Ludwig Lausanne's Ping-Chih Ho has been recognized by the American Association for the Advancement of Science (AAAS) for his distinguished contributions to immune metabolism. His research focuses on elucidating the role of metabolism in anti-tumor immunity and advancing cancer therapy.
A global panel of experts recommends a 10-year trial with 5,000 participants at high risk of cancer due to pre-cursor conditions. The trial will evaluate the potential efficacy of GLP-1 and dual receptor agonists in preventing obesity-related cancers.
The phase III Alliance ATOMIC trial shows that adding immunotherapy to standard chemotherapy improves clinical outcomes for patients with stage III dMMR colon cancer. The study found a 50% reduction in cancer recurrence risk and a 86.3% disease-free survival rate at three years.
A recent review highlights how immune cells synthesize and release neurotransmitters to modulate immune responses, blurring the boundaries between the nervous and immune systems.
Researchers found that breast cancer cells trigger the lung's natural repair system, leading to chronic inflammation and promoting tumor growth. A repurposed drug, roflumilast, may slow this process by preventing the lung environment from aiding tumor growth.